Deucravacitinib

Overview

Deucravacitinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4435170).

API suppliers (10)

Suppliers of Deucravacitinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• ALIVUS LIFE SCIENCES LTDIndia1 active DMF
• CHANGZHOU PHARMACEUTICAL FACTORYChina1 active DMF
• Cipla USA, Inc.USA1 active DMF
• CURIA SPAIN SAUSpain1 active DMF
• Dr. Reddy's Laboratories Ltd.India1 active DMF
• Macleods Pharmaceuticals Ltd.India1 active DMF
• MOEHS IBERICA SLSpain1 active DMF
• MSN Laboratories Private LimitedIndia1 active DMF
• XUZHOU WANBANG JINQIAO PHARMA CO LTDChina1 active DMF
• Zydus Lifesciences LimitedIndia1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Deucravacitinib expires 11 Feb 2043 and exclusivity 6 Mar 2029. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide

Canonical SMILES

[2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4

InChIKey

BZZKEPGENYLQSC-FIBGUPNXSA-N